Pluri (NASDAQ: PSTI)
Pluri Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Pluri Company Info
Pluri, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.
News & Analysis
Are Stem Cells the COVID-19 Treatment We've All Been Waiting For?
Promising results from a very small study caused shares of stem cell stocks to soar, but investors shouldn't get too carried away just yet.
Here's Why Pluristem Therapeutics Jumped Over 28% Today
The stem cell developer found a financing solution that won't dilute shareholders. Well, not immediately, anyway.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.